Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Apotex Rolls Out Pegfilgrastim A Year After Canadian Approval

Executive Summary

Apotex is rolling out its Lapelga pegfilgrastim biosimilar across Canada, almost a year after securing marketing authorization. But Mylan is seeking local reimbursement for its Fulphila alternative.

You may also be interested in...



Apotex Begins Roll Out Of Avastin Biosimilar In Canada

Following recent Health Canada approval, Apotex has launched partner mAbxience’s Bambevi (bevacizumab) biosimilar across Canada, adding to its portfolio of biosimilars that includes both filgrastim and pegfilgrastim.

Apotex Breaks New Ground In Canada With Biosimilar Bevacizumab

Apotex has received Health Canada approval for its Bambevi bevacizumab rival to Avastin, with the firm citing the nod as a first for its Apobiologix division.

Sandoz’ Ziextenzo And Riximyo Cleared In Canada

Sandoz Canada is looking to bolster its portfolio of biosimilars after obtaining marketing authorizations for both pegfilgrastim and rituximab.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB140136

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel